Amgen EVP exercises options, sells 54,792 shares

Amgen EVP of Operations Esteban Santos exercised stock options and sold shares.

Rhea-AI Filing Summary

Amgen EVP of Operations Esteban Santos exercised stock options and sold shares. On February 26, 2026, he exercised nonqualified stock options for 30,501 and 24,291 shares of Amgen common stock at exercise prices of $162.6000 and $177.4600 per share, respectively, and received common stock through derivative exercises.

On the same date, he sold 30,501 and 24,291 shares of common stock in open-market transactions at an average price of $379.1173 per share, for total sales of 54,792 shares, including shares sold to cover the option exercise price and required withholding taxes. After these transactions, he directly owned 76,618 shares and held an additional 903.8036 shares indirectly through the company’s 401(k) plan.

Insider Trade Summary

Exercise and Sale: 54,792 shares ($11.50M approx. pre-tax spread)

Exercise and Sale 7 txns

Insider Santos Esteban

Role EVP, Operations

Sold 54,792 shs ($20.77M)

Approx. gross sale proceeds $20.77M

Approx. exercise cost $9.27M

Approx. pre-tax spread $11.50M

Type	Security	Shares	Price	Value
Exercise	Nqso (Right to Buy)	30,501	$0.00	$0.00
Exercise	Nqso (Right to Buy)	24,291	$0.00	$0.00
Exercise	Common Stock	30,501	$162.60	$4.96M
Sale	Common Stock	30,501	$379.1173	$11.56M
Exercise	Common Stock	24,291	$177.46	$4.31M
Sale	Common Stock	24,291	$379.1173	$9.21M
holding	Common Stock	--	--	--

Holdings After Transaction: Nqso (Right to Buy) — 0 contracts (Direct); Common Stock — 76,618 shares (Direct); Common Stock — 903.8036 shares (Indirect, 401K Plan)

Footnotes (4)

1. F1. Includes shares sold to cover the option exercise price and required withholding taxes in connection with the exercise of expiring options.
2. F2. The price reported is an average price of $379.1173 per share. Full information regarding the number of shares purchased at each separate price within the range is available upon request by the SEC staff, the issuer or a security holder of the issuer
3. F3. These shares include 624 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
4. F4. These shares are acquired under the Company's 401(k) Plan and represent interests in the Company's stock fund as of this filing.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Amgen (AMGN) EVP Esteban Santos report on this Form 4?

Amgen EVP of Operations Esteban Santos reported exercising nonqualified stock options and related open-market sales. He converted options into common shares, then sold 54,792 shares, including shares used to cover exercise costs and required withholding taxes, all on February 26, 2026.

How many Amgen (AMGN) shares did Esteban Santos sell in this filing?

Esteban Santos sold a total of 54,792 Amgen common shares. These consisted of two sales of 30,501 and 24,291 shares in open-market or private transactions, executed at an average price of $379.1173 per share, as disclosed in the Form 4 footnotes.

What option exercises did Esteban Santos disclose for Amgen (AMGN)?

He disclosed exercising two nonqualified stock option grants covering 30,501 and 24,291 shares. The underlying options had exercise prices of $162.6000 and $177.4600 per share, respectively, and were exercised on February 26, 2026, converting derivative awards into Amgen common stock.

What were Esteban Santos’s Amgen (AMGN) holdings after these transactions?

Following the reported exercises and sales, Esteban Santos directly held 76,618 Amgen common shares. He also indirectly held 903.8036 additional shares through the company’s 401(k) plan, representing interests in Amgen’s stock fund as of the filing date.

At what price were the Amgen (AMGN) shares sold by Esteban Santos?

The reported sales were executed at an average price of $379.1173 per share. A footnote explains this is a volume-weighted average, and more detailed price breakdowns for each trade within the range are available upon request from the SEC staff, issuer, or shareholders.

Did Esteban Santos use some Amgen (AMGN) shares to cover option costs or taxes?

Yes. A footnote states the reported sales include shares sold to cover the option exercise price and required withholding taxes. This means part of the 54,792 shares sold were used to satisfy the financial obligations associated with exercising expiring stock options.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/02/2026 - 07:20 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Santos Esteban

(Last) (First) (Middle)

ONE AMGEN CENTER DRIVE

(Street)

THOUSAND OAKS CA 91320-1799

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
AMGEN INC [ AMGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Operations

3. Date of Earliest Transaction (Month/Day/Year)
02/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/26/2026		M		30,501	A	$162.6	107,119	D
Common Stock	02/26/2026		S		30,501(1)	D	$379.1173(2)	76,618	D
Common Stock	02/26/2026		M		24,291	A	$177.46	100,909	D
Common Stock	02/26/2026		S		24,291(1)	D	$379.1173(2)	76,618(3)	D
Common Stock								903.8036(4)	I	401K Plan

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Nqso (Right to Buy)	$162.6	02/26/2026		M			30,501	05/01/2019	05/01/2027	Common Stock	30,501	$0	0	D
Nqso (Right to Buy)	$177.46	02/26/2026		M			24,291	04/27/2020	04/27/2028	Common Stock	24,291	$0	0	D

Explanation of Responses:

1. Includes shares sold to cover the option exercise price and required withholding taxes in connection with the exercise of expiring options.

2. The price reported is an average price of $379.1173 per share. Full information regarding the number of shares purchased at each separate price within the range is available upon request by the SEC staff, the issuer or a security holder of the issuer

3. These shares include 624 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

4. These shares are acquired under the Company's 401(k) Plan and represent interests in the Company's stock fund as of this filing.

	/s/ Esteban Santos	02/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.